Proteomic analysis of pulmonary arterial hypertension

Abstract

Pulmonary arterial hypertension (PAH) is a rare but fatal cardiovascular disorder with high morbidity and mortality. Diagnosis and treatment of this disease at an early stage would greatly improve outcomes. The molecular indicators of PAH are mostly nonspecific, and diagnostic and prognostic biomarkers are urgently needed. A more comprehensive understanding of the molecular mechanisms underlying this complex disease is crucial for the development of new and more effective therapeutics to improve patient outcomes. In this article, we review published literature on proteomic biomarkers and underlying molecular mechanisms in PAH and their value for disease management, aiming to deepen our understanding of the disease and, ultimately, pave the way for clinical application.

Proteomic analysis of pulmonary arteries and lung tissues from dogs affected with pulmonary hypertension secondary to degenerative mitral valve disease

“…The use of LC-MS/MS based proteomic analysis to understand the pathogenesis of PH has been widely studied in human patients and animal models [17]. Many of these proteomic investigations have focused on lung tissues, which are composed of a variety of cell types and may not be the exact location of the pathological alterations in PH.…”

“…Findings from several proteomic studies have summarized those mechanisms such as mitochondrial dysfunction and metabolic shifts, nitric oxide production and responsiveness, coagulation and fibrinolysis, immune and inflammation responses and apoptosis resistance are associated with PH. The information provides valuable insights for further indepth research [17]. While many proteomic studies have been performed to uncover mechanisms underlying PH in human patients and animal models, no work has been performed on the lung or pulmonary artery proteome in dogs affected with PH secondary to DMVD.…”

Risk Stratification in Pulmonary Arterial Hypertension, Update and Perspectives

“…Research is underway to provide stronger evidence for the use of proteomics as prognostic factors of PAH [ 38 , 39 , 40 ]. With proteomic techniques, the profiling of human plasma proteome becomes more feasible in searching for disease-related markers.…”

Increased plasma expression of a disintegrin and metalloproteinase with thrombospondin motifs like 4 in patients with idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension

“…The mechanisms underlying pulmonary vascular remodeling in both IPAH and CTEPH remain poorly understood 1 . Due to this knowledge gap, molecular indicators are needed to aid in diagnosing and predicting the prognosis of pulmonary hypertension (PH) 2 . Potential molecular indicators include chemokine CXC ligand 13, pentraxin 3, and N‐terminal pro‐brain natriuretic peptide (NT‐proBNP); however, their diagnostic and evaluative values require large‐scale validation 3–5 .…”

“…1 Due to this knowledge gap, molecular indicators are needed to aid in diagnosing and predicting the prognosis of pulmonary hypertension (PH). 2 Potential molecular indicators include chemokine CXC ligand 13, pentraxin 3, and N‐terminal pro‐brain natriuretic peptide (NT‐proBNP); however, their diagnostic and evaluative values require large‐scale validation. 3 , 4 , 5 Proteomics analysis offers a comprehensive approach for identifying novel indicators by examining the complete protein profiles associated with these conditions.…”